A concise review of the cost-effectiveness of coronary heart disease prevention

被引:14
|
作者
Brown, AID
Garber, AM
机构
[1] Stanford Univ, Ctr Primary Care & Outcomes Res, Ctr Hlth Policy, Stanford, CA 94305 USA
[2] Univ Oxford, Dept Publ Hlth & Primary Care, Oxford OX3 7LF, England
[3] Univ Toronto, Dept Hlth Adm, Toronto, ON M5S 1A1, Canada
[4] Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA
关键词
D O I
10.1016/S0025-7125(05)70219-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronary heart disease is one of the largest sources of morbidity, mortality, and health care expenditure in the United States. This article reviews a number of studies that estimate the cost per unit of health benefits associated with different primary and secondary prevention strategies for coronary heart disease. Although prevention does not provide a panacea for rising health care spending, many preventive strategies are cost-effective when compared to other common clinical interventions. Prevention should be incorporated into regular clinical practice.
引用
收藏
页码:279 / +
页数:20
相关论文
共 50 条
  • [21] Cost-effectiveness of cardiovascular imaging for stable coronary heart disease
    Walker, Simon
    Cox, Edward
    Rothwell, Ben
    Berry, Colin
    McCann, Gerry P.
    Bucciarelli-Ducci, Chiara
    Dall'Armellina, Erica
    Prasad, Abhiram
    Foley, James Robert John
    Mangion, Kenneth
    Bijsterveld, Petra
    Everett, Colin
    Stocken, Deborah
    Plein, Sven
    Greenwood, John P.
    Sculpher, Mark
    HEART, 2021, 107 (05) : 381 - 388
  • [22] Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults
    Adalsteinn D. Brown
    Alan M. Garber
    PharmacoEconomics, 1998, 14 : 27 - 48
  • [23] Cost effectiveness of coronary heart disease prevention strategies in adults
    Brown, AD
    Garber, AM
    PHARMACOECONOMICS, 1998, 14 (01) : 27 - 48
  • [24] Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada
    Riviere, M
    Wang, SS
    Leclerc, C
    Fitzsimon, C
    Tretiak, R
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1997, 156 (07) : 991 - 997
  • [25] Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan
    Nagata-Kobayashi, S
    Shimbo, T
    Matsui, K
    Fukui, T
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 104 (02) : 213 - 223
  • [26] Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis
    Morton, Jedidiah I. Z. I.
    Marquina, Clara
    Lloyd, Melanie
    Watts, Gerald F. F.
    Zoungas, Sophia
    Liew, Danny
    Ademi, Zanfina
    PHARMACOECONOMICS, 2024, 42 (01) : 91 - 107
  • [27] Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis
    Jedidiah I. Morton
    Clara Marquina
    Melanie Lloyd
    Gerald F. Watts
    Sophia Zoungas
    Danny Liew
    Zanfina Ademi
    PharmacoEconomics, 2024, 42 : 91 - 107
  • [28] PRIMARY PREVENTION OF CORONARY HEART-DISEASE IN THE FEDERAL-REPUBLIC-OF-GERMANY ANALYSIS OF COST-EFFECTIVENESS
    ASSMANN, G
    SCHULTE, H
    DRUGS, 1990, 40 : 33 - 37
  • [29] Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke
    Heller, David J.
    Coxson, Pamela G.
    Penko, Joanne
    Pletcher, Mark J.
    Goldman, Lee
    Odden, Michelle C.
    Kazi, Dhruv S.
    Bibbins-Domingo, Kirsten
    CIRCULATION, 2017, 136 (12) : 1087 - +
  • [30] Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men
    Peura, Piia
    Martikainen, Janne
    Soini, Erkki
    Hallinen, Taru
    Niskanen, Leo
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (06) : 1823 - 1832